Alan joined Advent in 2013 and brings 27 years of industry experience in corporate venture capital, business development, R and D, and general management at Genzyme Corporation.

Alan most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures), where he was responsible for identifying and closing several new investments, and for managing a portfolio of direct and LP investments. Alan earlier led business and corporate development activities in Genzyme’s Therapeutics business, where he initiated and executed a number of transactions and new business initiatives that led to several innovative marketed products. Alan’s roles at Genzyme also included President of Genzyme Pharmaceuticals and head of chemistry and biopolymer research.

Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School in 1993.

In addition to his role at Advent, Alan currently works as a business advisor to Belinda Termeer, the widow of Genzyme’s former Chairman and CEO, Henri Termeer, and is a founder and Director of The Termeer Foundation.  Alan has co-founded several companies with Advent and is also a board member and advisor to several life science companies. Since joining Advent, Alan has been involved in several portfolio companies including Aura, Levicept and Zikani.

Alan is currently Chairman of PIC Therapeutics, a board member at Eloxx and Artax, a co-founder and board observer of Arrakis, a board observer at Aleta, and a co-founder and Chief Scientific Officer at Manta Medicines.

Back to Team